Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.67 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680737 | 0.89 | PDE2A (0.64) | PDE2APDE10AALDH1A1LMNAMAPT | |
| SCHEMBL955665 | 0.86 | PDE2A (0.77) | PDE2APDE10AALDH1A1LMNAMAPT | |
| SCHEMBL1081550 | 0.85 | PDE2A (0.69) | PDE2AALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL6349005 | 0.85 | PDE2A (0.69) | PDE2AALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL958299 | 0.84 | PDE2A (0.49) | PDE2AMAPK14ALDH1A1LMNAMAPT | |
| SCHEMBL2680564 | 0.84 | PDE2A (0.67) | PDE2AALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL6350615 | 0.84 | PDE2A (0.67) | PDE2AALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL961084 | 0.84 | PDE2A (0.76) | PDE2APDE10AALDH1A1LMNAMAPT | |
| SCHEMBL17004372 | 0.83 | PDE2A (0.48) | PDE2APDE10AMAPK14ALDH1A1LMNA | |
| SCHEMBL2680376 | 0.83 | PDE2A (0.69) | PDE2AALDH1A1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | claimed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | claimed |
| EP-2456440-A1 | QUINOLINONE PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-05-30 | — | — | EP | claimed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | claimed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | PDE12, PDE2A, PDE4A | PDE2A 2/4885PDE10A 22/4885MAPK14 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.